Anthem BioSciences

As of the close on 5 November 2026, ANTHEM trades at ₹911.85, reflecting a +2.7% daily gain and a strong upward gap. The stock is positioned near the upper end of its recent trading ranges (+96.5% in the 20-day range, +83.5% in the 252-day range), indicating significant relative strength. Price action remains above all key moving averages (EMA/SMA 20/50/200) and the Supertrend across daily, weekly, and monthly timeframes, confirming a structural uptrend.

Trend conviction varies by horizon: the weekly (ADX 32.04) and monthly (ADX 29.94) trends are established with bullish directional indicators (+DI > -DI), while the daily trend (ADX 22.04) is developing. Recent anomalies include a high-severity upward gap on 5 November and volume-backed price moves on 4 November, suggesting active participation. Risk metrics show an annualized volatility of +30.7% and a current drawdown of -4.8% from the available high. Immediate resistance lies at ₹922.50 (+1.17%), with support at ₹905.40 (-0.71%). A sustained hold above the 20-day EMA and Supertrend would reinforce the bullish structure, while a break below ₹905.40 could signal short-term consolidation.

On November 6, 2026, Anthem Biosciences Limited was identified as a top stock recommendation by Hitesh Rathi, Technical Analyst at Angel One. The selection was based on specific technical indicators, including W-pattern breakouts, bullish bear traps, and support confluences, which the analyst cited as signals for continued upward momentum. This report represents third-party technical analysis rather than a corporate announcement or fundamental business development from the company itself.

Anthem Biosciences Limited (NSE: ANTHEM) has seen a material shift in market sentiment and technical positioning as of early November 2026. On November 5, 2026, the stock price rose to ₹911.85, up from ₹888.30 on the previous observation date, reflecting a positive technical breakout. This upward momentum was reinforced by analyst recommendations from Angel One on November 6, 2026, which cited W-pattern breakouts and bullish bear traps as indicators for continued strength.

Corporate activity also updated during this period. On November 5, 2026, the company filed with the NSE to make available the audio recording of its earnings call held on November 4, 2026. The call covered unaudited financial results for the quarter and half-year ended September 30, 2026. While the specific financial figures from the call are not detailed in the current evidence, the availability of the recording signals transparency regarding recent operational performance.

The combination of technical buy signals and fresh investor communication marks a change from prior static periods. Investors should monitor whether the technical momentum sustains following the release of the earnings call details.

Anthem Biosciences Limited has released its unaudited financial results for the quarter and half-year ended September 30, 2026 (Q2 & H1 FY27), approved by the Board on November 3, 2026. The company reported consolidated revenue from operations of ₹5,940 million for Q2FY27, marking a 7.9% year-on-year increase, while H1FY27 revenue stood at ₹10,123 million, down 7.2% year-on-year. Profit After Tax (PAT) improved significantly in Q2FY27 to ₹2,115 million (up 21.9% YoY), with an EBITDA margin expansion to 44.5%-50.6% depending on the specific reporting line, driven by cost efficiencies and forex gains. The company maintains a strong net cash position of ₹15,380 million as of September 30, 2026. Additionally, 143,285 equity shares were allotted under the Employee Stock Option Plan 2024 during the quarter. An earnings call was held on November 4, 2026, and the company will participate in the JM Financial India Xchange 2026 in Mumbai from November 16-18, 2026.

Anthem Biosciences demonstrates a robust operational turnaround in Q2 FY2026-27, marked by strong sequential growth and significant balance-sheet deleveraging. Revenue from operations rose to ₹594 crore from ₹418 crore in Q1, driving Profit Before Tax (PBT) to ₹296 crore and Net Profit to ₹211 crore, compared to ₹120 crore in the prior quarter. This profitability surge is supported by a sharp reduction in finance costs, which fell from ₹88.7 lakh to ₹3.31 crore, reflecting a broader trend of debt reduction where borrowings declined to ₹40 crore as of September 2026.

Earnings quality has improved markedly, with Cash Flow from Operations (CFO) reaching ₹844 crore for the year ended March 2026, converting at 126% of operating profit. Working capital efficiency also shows structural improvement, with the Cash Conversion Cycle compressing significantly to 124 days by March 2026, driven primarily by a drop in Inventory Days to 56. While TTM sales show a slight contraction (-1%), the underlying momentum is evident in the 26% YoY sales growth recorded in March 2026 and consistent quarterly expansion. The company’s asset base expanded to ₹3,686 crore, with non-current assets rising to ₹1,805 crore, indicating continued investment in fixed capacity alongside reduced current liabilities.

The most critical next checkpoint is monitoring whether this high level of cash generation and margin expansion sustains as the company integrates its growing fixed-asset base into revenue streams, particularly given the recent dip in TTM top-line growth.

Anthem Biosciences presents a conditional upside case anchored in multi-timeframe technical strength and recent momentum. As of November 5, 2026, the stock closed at ₹911.85, reflecting a robust year-to-date return of +42.9% and a one-year gain of +29.8%. The weekly trend is explicitly bullish, with the Supertrend direction signaling upward momentum and positive slope indicators for both the 20-period (17.98) and 50-period (15.95) simple moving averages. This structural alignment suggests that despite a current short-term drawdown of -4.8%, the broader intermediate-term trajectory remains intact. Additionally, analyst commentary from November 6, 2026, highlights technical patterns such as W-pattern breakouts and bullish bear traps, reinforcing the view of continued upward potential if price action holds above key support levels like ₹905.4.